Recurrent meningitis: Difference between revisions
From IDWiki
Content deleted Content added
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==Etiologies== |
|||
==Differential Diagnosis== |
|||
| ⚫ | |||
| ⚫ | |||
**Bacterial: [[Streptococcus pneumoniae]], [[Haemophilus influenzae]], [[Neisseria meningitidis]], [[Staphylococcus aureus]], [[Escherichia coli]] |
|||
**Fungal: [[Cryptococcus neoformans]], [[Candida]], [[Histoplasma capsulatum]], [[Coccidioides immitis]], [[Blastomyces dermatitidis]] |
|||
**Parasitic: [[Echinococcus]], [[Strongyloides stercoralis]], [[Toxoplasma gondii]] |
|||
*Malignancy: leptomeningeal metastaisis from solid malignancy, leukemic meningitis, lymphomatous meningitis |
|||
*Benign tumours: epidermoid cyst, dermoid cyst, craniopharyngioma |
|||
*Medications |
|||
**NSAIDs: [[ibuprofen]] (most common), [[diclofenac]], [[naproxen]], [[sulindac]] |
|||
**Antibiotics: [[cotrimoxazole]], [[cephalosporins]], [[amoxicillin]], [[ciprofloxacin]] |
|||
**Antiepileptics: [[lamotrigine]], [[carbamazepine]] |
|||
**Chemotherapy: [[cetuximab]], intrathecal chemotherapy |
|||
**Immunosuppression: [[methotraxate]], [[azathioprine]], [[TNF-alpha inhibitors]] ([[adalimumab]], [[infliximab]], [[etanercept]]) |
|||
| ⚫ | |||
*Immune defects |
*Immune defects |
||
**[[Asplenia]] |
**[[Asplenia]] |
||
**[[Hypogammaglobulinemia]] |
**[[Hypogammaglobulinemia]] |
||
**[[Complement deficiencies]], including [[properdin deficiency]], [[terminal complement deficiency]], and use of [[eculizumab]] |
**[[Complement deficiencies]], including [[properdin deficiency]], [[terminal complement deficiency]], and use of [[eculizumab]] |
||
| ⚫ | |||
*Parameningeal focus of infection |
|||
*Structural abnormalities |
|||
**Post-neurosurgery |
|||
**[[CSF leak]] or [[CSF fistula]] |
|||
**[[Dermal sinus]] |
|||
**[[Epidermoid cyst]] |
|||
**[[Craniopharyngioma]] |
|||
*Drugs |
|||
**[[TMP-SMX]] |
|||
**[[NSAIDs]] |
|||
| ⚫ | |||
**OKT3 |
|||
**[[Phenytoin]] |
|||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
**[[SLE]] |
**[[SLE]] |
||
**[[Behçet disease]] |
**[[Behçet disease]] |
||
**[[Sarcoidosis]] |
|||
**[[Sjögren syndrome]] |
|||
**[[Vogt-Koyanagi-Harada syndrome]] |
|||
**[[Granulomatosis with polyangiitis]] |
|||
**[[Rheumatoid arthritis]] |
|||
==Specific Patients== |
==Specific Patients== |
||
| Line 35: | Line 39: | ||
**[[Enterovirus]] |
**[[Enterovirus]] |
||
**[[Mycoplasma]] |
**[[Mycoplasma]] |
||
== Further Reading == |
|||
* Recurrent Meningitis. ''Curr Pain Headache Rep''. 2017;21(33). doi: [https://doi.org/10.1007/s11916-017-0635-7 10.1007/s11916-017-0635-7] |
|||
[[Category:CNS infections]] |
[[Category:CNS infections]] |
||
Revision as of 15:42, 18 September 2025
Etiologies
- Infections
- Viral: HSV-2 (Mollaret's disease; most common cause); HSV-1; EBV
- Bacterial: Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis, Staphylococcus aureus, Escherichia coli
- Fungal: Cryptococcus neoformans, Candida, Histoplasma capsulatum, Coccidioides immitis, Blastomyces dermatitidis
- Parasitic: Echinococcus, Strongyloides stercoralis, Toxoplasma gondii
- Malignancy: leptomeningeal metastaisis from solid malignancy, leukemic meningitis, lymphomatous meningitis
- Benign tumours: epidermoid cyst, dermoid cyst, craniopharyngioma
- Medications
- NSAIDs: ibuprofen (most common), diclofenac, naproxen, sulindac
- Antibiotics: cotrimoxazole, cephalosporins, amoxicillin, ciprofloxacin
- Antiepileptics: lamotrigine, carbamazepine
- Chemotherapy: cetuximab, intrathecal chemotherapy
- Immunosuppression: methotraxate, azathioprine, TNF-alpha inhibitors (adalimumab, infliximab, etanercept)
- Other: IVIg
- Immune defects
- Asplenia
- Hypogammaglobulinemia
- Complement deficiencies, including properdin deficiency, terminal complement deficiency, and use of eculizumab
- Inflammatory/autoimmune
Specific Patients
Terminal Complement Deficiency
- Prone to recurrent neisserial infections
Hypogammaglobulinemia
- Can develop chronic meningoencephalitis, primarily cause by:
Further Reading
- Recurrent Meningitis. Curr Pain Headache Rep. 2017;21(33). doi: 10.1007/s11916-017-0635-7